Bristol-Myers stock could be worth $64-$74 per share, says Goldman Sachs
Goldman Sachs analyst Jami Rubin believes that Bristol-Myers could be worth $64-$74 per share ,depending on the outcome of a trial of its CM-227 cancer treatment. The analyst notes that if the trial is successful, the company will have the only IO treatment that works in conjunction with the CTLA-4 protein receptor, and Rubin says this will be "particularly meaningful"if patients taking CM-227 show.a higher overall survival rate than those taking chom combos. Rubin thinks the stock could be worth $59-$75 per share in a takeover with no value for CM-227, and the analyst says that at $50 per share the stock is reflecting no value for the company's first line NSCLC treatment. Rubin keeps the stock on the Americas Buy List.